SCHEMBL6997428

SCHEMBL6997428

N#Cc1ccc(S(=O)(=O)CCCN2CC3CC(C2)CN(Cc2ccc(F)cc2)C3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.41
DRD3 P35462 4/20 0.41
CCR3 P51677 1/20 0.39
THRB P10828 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
KCNH2 Q12809 1/20 0.38
PRKAA2 P54646 3/20 0.38
PRKAB2 O43741 2/20 0.38
PRKAG1 P54619 2/20 0.38
PRKAA1 Q13131 2/20 0.38
PRKAG3 Q9UGI9 2/20 0.38
PRKAG2 Q9UGJ0 2/20 0.38
PRKAB1 Q9Y478 2/20 0.38
CACNA1F O60840 1/20 0.37
HTR1A P08908 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
DRD1 P21728 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963311 0.88 KCNH2 (0.47) DRD2DRD3CCR3THRBHTR2A
SCHEMBL7166309 0.86 DRD2 (0.39) DRD2DRD3CCR3THRBHTR2A
SCHEMBL5965538 0.85 DRD3 (0.40) DRD2DRD3CCR3THRBHTR2A
SCHEMBL7028285 0.81 CYP19A1 (0.38) KCNH2HRH2HTR7HRH1HTR6
SCHEMBL6995086 0.81 CCR3 (0.49) DRD2DRD3CCR3CYP11B1CYP11B2
SCHEMBL6996965 0.80 SIGMAR1 (0.41) DRD2DRD3THRBHRH2HTR7
SCHEMBL6996340 0.78 S1PR5 (0.45) DRD2DRD3PRKAA2HRH2HRH1
SCHEMBL6995153 0.78 CCR3 (0.52) CCR3PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL7033710 0.77 HRH2 (0.38) KCNH2HRH2HTR7HRH1
SCHEMBL6997410 0.76 EBP (0.45) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E DRD2 28/4885DRD3 51/4885CCR3 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.